AMARIN CORP PLC\UK
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES Power of Attorney
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AMARIN CORPORATION PLC | |
|---|---|
| By: | /s/ Aaron Berg |
| Aaron Berg | |
| President and Chief Executive Officer(Principal Executive Officer) | |
Date: March 2, 2026
We, the undersigned officers and directors of the Registrant hereby severally constitute and appoint Aaron Berg and Peter Fishman, and each of them singly, our true and lawful attorneys, with full power to them and each of them singly, to sign for us in our names in the capacities indicated below, all amendments to this report, and generally to do all things in our names and on our behalf in such capacities to enable the Registrant to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all requirements of the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Aaron Berg Aaron Berg | Director, President and ChiefExecutive Officer (PrincipalExecutive Officer) | March 2, 2026 |
| /s/ Peter Fishman Peter Fishman | Senior Vice President and ChiefFinancial Officer (PrincipalFinancial and Accounting Officer) | March 2, 2026 |
| /s/ Patrice Bonfiglio Patrice Bonfiglio | Director | March 2, 2026 |
| /s/ Paul Cohen, M.D. Paul Cohen, M.D. | Director | March 2, 2026 |
| /s/ Keith L. Horn Keith L. Horn | Director | March 2, 2026 |
| /s/ Odysseas Kostas, M.D. | Director | March 2, 2026 |
| Odysseas Kostas, M.D. | ||
| /s/ Louis Sterling III. Louis Sterling III. | Director | March 2, 2026 |
| /s/ Diane E. Sullivan Diane E. Sullivan | Director | March 2, 2026 |
| /s/ Oliver O'Connor | Director | March 2, 2026 |
| Oliver O'Connor | ||
| /s/ Michael Torok | Director | March 2, 2026 |
| Michael Torok | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 42) | F-2 |
|---|---|
| Financial Statements: | |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
| Financial Statement Schedules: | |
Financial statement schedules have been omitted for the reason that the required information is presented in the consolidated financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.